JP2005503102A - 多重系統キナーゼタンパク質の調節および多重系統キナーゼタンパク質を調節する化合物のスクリーニング方法。 - Google Patents

多重系統キナーゼタンパク質の調節および多重系統キナーゼタンパク質を調節する化合物のスクリーニング方法。 Download PDF

Info

Publication number
JP2005503102A
JP2005503102A JP2002519661A JP2002519661A JP2005503102A JP 2005503102 A JP2005503102 A JP 2005503102A JP 2002519661 A JP2002519661 A JP 2002519661A JP 2002519661 A JP2002519661 A JP 2002519661A JP 2005503102 A JP2005503102 A JP 2005503102A
Authority
JP
Japan
Prior art keywords
carbons
group
alkyl
compound
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002519661A
Other languages
English (en)
Japanese (ja)
Inventor
マロニー，アンナ
ウオルトン，ケビン・エム
デイオン，クレイグ・エイ
ネフ，ニコラ
ナイト，アーネスト，ジユニア
グリクスマン，マーシー・エイ
Original Assignee
セフアロン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セフアロン・インコーポレーテツド filed Critical セフアロン・インコーポレーテツド
Publication of JP2005503102A publication Critical patent/JP2005503102A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Wood Science & Technology (AREA)
JP2002519661A 2000-08-11 2001-08-08 多重系統キナーゼタンパク質の調節および多重系統キナーゼタンパク質を調節する化合物のスクリーニング方法。 Pending JP2005503102A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63705400A 2000-08-11 2000-08-11
PCT/US2001/024822 WO2002014536A2 (en) 2000-08-11 2001-08-08 Odulating multiple lineage kinase proteins

Publications (1)

Publication Number Publication Date
JP2005503102A true JP2005503102A (ja) 2005-02-03

Family

ID=24554347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002519661A Pending JP2005503102A (ja) 2000-08-11 2001-08-08 多重系統キナーゼタンパク質の調節および多重系統キナーゼタンパク質を調節する化合物のスクリーニング方法。

Country Status (19)

Country Link
EP (1) EP1309721A2 (zh)
JP (1) JP2005503102A (zh)
CN (1) CN1458979A (zh)
AU (2) AU2001283179B2 (zh)
BG (1) BG107623A (zh)
BR (1) BR0113266A (zh)
CA (1) CA2419985A1 (zh)
CZ (1) CZ2003680A3 (zh)
HR (1) HRP20030162A2 (zh)
HU (1) HUP0501110A3 (zh)
IL (1) IL154311A0 (zh)
IS (1) IS6711A (zh)
MX (1) MXPA03001218A (zh)
NO (1) NO20030658L (zh)
NZ (1) NZ524034A (zh)
PL (1) PL366248A1 (zh)
SK (1) SK2692003A3 (zh)
WO (1) WO2002014536A2 (zh)
ZA (1) ZA200301109B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
AU2004257748B2 (en) * 2003-07-14 2008-10-30 Decode Genetics Ehf. Method of diagnosis and treatment for asthma based on haplotype association
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
WO2014172616A2 (en) * 2013-04-18 2014-10-23 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
NZ754020A (en) * 2016-11-25 2022-11-25 Genuv Inc Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
ATE293254T1 (de) * 1998-08-26 2005-04-15 Cephalon Inc Modulierung von mlk- (multiple lineage kinase) proteinen
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones

Also Published As

Publication number Publication date
PL366248A1 (en) 2005-01-24
WO2002014536A9 (en) 2003-12-18
BG107623A (bg) 2003-11-28
HUP0501110A3 (en) 2006-06-28
HUP0501110A2 (en) 2006-03-28
SK2692003A3 (en) 2003-08-05
IS6711A (is) 2003-02-10
WO2002014536A2 (en) 2002-02-21
CA2419985A1 (en) 2002-02-21
CZ2003680A3 (cs) 2003-11-12
NO20030658D0 (no) 2003-02-10
ZA200301109B (en) 2004-07-20
AU2001283179B2 (en) 2006-07-13
NZ524034A (en) 2006-11-30
NO20030658L (no) 2003-04-09
CN1458979A (zh) 2003-11-26
AU8317901A (en) 2002-02-25
IL154311A0 (en) 2003-09-17
MXPA03001218A (es) 2003-05-27
HRP20030162A2 (en) 2005-12-31
WO2002014536A3 (en) 2003-01-30
EP1309721A2 (en) 2003-05-14
BR0113266A (pt) 2005-01-04

Similar Documents

Publication Publication Date Title
EP1105728B1 (en) Modulating multiple lineage kinase proteins
Quach et al. Involvement of collapsin response mediator proteins in the neurite extension induced by neurotrophins in dorsal root ganglion neurons
JP4481493B2 (ja) 架橋インデノピロロカルバゾール
PL212956B1 (pl) Zastosowanie zwiazku o wzorze I lub II, zwiazek o wzorze II, oraz kompozycja farmaceutyczna zawierajaca zwiazek o wzorze II
JP2005503102A (ja) 多重系統キナーゼタンパク質の調節および多重系統キナーゼタンパク質を調節する化合物のスクリーニング方法。
AU2001283179A1 (en) Modulating multiple lineage kinase proteins
US9440980B2 (en) Remedy for diabetes
MXPA01006987A (es) Uso de contrapartes de union de los receptores 5-ht5 para el tratamiento de trastornos neurodegenerativos y neurosiquiatricos.
MXPA01002020A (en) Modulating multiple lineage kinase proteins
Dumoulin et al. Transplantation of embryonic Raphe cells regulates the modifications of the GABAergic phenotype occurring in the injured spinal cord
EP1608376A2 (en) ACTIVATION SPECIFIC INHIBITORS OF NF-kB AND METHOD OF TREATING INFLAMMATORY PROCESSES IN CARDIO-VASCULAR DISEASES
WO2005106473A1 (ja) 神経変性疾患治療薬のスクリーニング方法
Wong Regulation of lipogenic gene transcription during fasting and feeding/insulin: Role of USF, SREBP-1c, and BAF60c

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080430